CY12-RP2 treatment significantly increased the density of tumor-infiltrating lymphocytes (p < 0.001), as evidenced by expansions in CD3+ T cells and prominent elevations in Granzyme B+CD8+ cytotoxic T lymphocytes (72.4% in CY12-RP2–treated mice vs 41.8% in controls; p < 0.01; Figures 5A, B). Here, CD8A is linked to neoplasm.